OasisLMS

In this episode of The Lead, host Christopher C. Cheung, MD, MPH, FHRS, is joined by Edward P. Gerstenfeld, MD, MS, FHRS, and Paul C. Zei, MD, PhD, FHRS, to discuss the journal article, A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD). Together, they review the study design and findings, examining pulsed field ablation and anti-arrhythmic drug therapy as first-line treatment approaches for patients with persistent atrial fibrillation.

• Review the design and key findings of the AVANT GUARD study comparing pulsed field ablation with anti-arrhythmic drug therapy as first-line treatment for persistent atrial fibrillation.
• Discuss the potential role of pulsed field ablation as an initial treatment strategy for patients with persistent atrial fibrillation.
• Examine the comparative considerations of ablation-based and pharmacologic approaches in the management of persistent atrial fibrillation.

Host: Christopher C Cheung, MD, MPH, FHRS       

Guests: Edward P. Gerstenfeld, MD, MS, FHRS

Paul C Zei, MD, PhD, FHRS

Christopher C Cheung, MD, MPH, FHRS

Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biotronik, Biosense Webster, Inc., Abbott

Edward P. Gerstenfeld, MD, MS, FHRS

Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Abbott, Boston Scientific, Varian Medical Systems

Other Non-Financial Relationships: Adagio Medical, Boston Scientific, Abbott Medical

Research: Abbott Medical

Officer, Trustee, Director, Committee Chair, or Other Fiduciary Role: American College of Cardiology

Paul C Zei, MD, PhD, FHRS

Honoraria/Speaking/Consulting Fee/Speaker’s Bureau: Varian Medical Systems, Biosense Webster, Inc., Abbott, Boston Scientific, APT Medical

Research: Biosense Webster, Inc.

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):